Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo

Oncology Reports

Volumn 16, Issue 4, 2006, Pages 811-815

  Quaresima, Barbara ^a   Faniello, Maria C ^a   Baudi, Francesco ^a   Crugliano, Telma ^a   Di Sanzo, Maddalena ^a   Cuda, Giovanni ^a   Costanzo, Francesco ^a   Venuta, Salvatore ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

BRCA1; BRCT; Missense mutations; p53

Indexed keywords

AGAR; PROTEIN P53;

ALLELE; ARTICLE; BIOLOGICAL MODEL; BREAST TUMOR; CELL PROLIFERATION; CHEMISTRY; ESCHERICHIA COLI; FEMALE; GENETICS; HELA CELL; HUMAN; IN VITRO STUDY; METABOLISM; MISSENSE MUTATION; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; TUMOR SUPPRESSOR GENE;

AGAR; ALLELES; BREAST NEOPLASMS; CELL PROLIFERATION; ESCHERICHIA COLI; FEMALE; GENES, BRCA1; HELA CELLS; HUMANS; MODELS, GENETIC; MUTATION, MISSENSE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33749818156     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.4.811     Document Type: Article

References (36)

1. Miki Y, Swensen J, Shattuck-Eidens D, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71, 1994.
2. Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE and King MC: Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 8: 399-404, 1994. (Pubitemid 24375608)
3. Chen Y, Farmer AA, Chen CF, Jones DC, Chen PL and Lee WH: BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res 56: 3168-3172, 1996. (Pubitemid 26242955)
4. Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF and Koonin EV: A superfamily of conserved domains in DNA damage-responsive cell cycle check-point proteins. FASEB J 11: 68-76, 1997.
5. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ and Qin J: BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 14: 927-939, 2000. (Pubitemid 30253002)
6. Wang Q, Zhang H, Guerrette S, Chen J, Mazurek A, Wilson T, Slupianek A, Skorski T, Fishel, R and Greene MI: Adenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1. Oncogene 20: 4640-4649, 2001. (Pubitemid 32762436)
7. Anderson SF, Schlegel BP, Nakajima T, Wolpin ES and Parvin JD: BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase. Nat Genet 19: 254-256, 1998. (Pubitemid 28309336)
8. Wang Q, Zhang H, Kajino K and Greene MI: BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. Oncogene 17: 1939-1948, 1998. (Pubitemid 28488462)
9. Schlegel BP, Green VJ, Ladias JA and Parvin JD: BRCA1 interaction with RNA polymerase II reveals a role for hRPB2 and hRPB10alpha in activated transcription. Proc Natl Acad Sci USA 97: 3148-3153, 2000. (Pubitemid 30183270)
10. Pao GM, Janknecht R, Ruffner H, Hunter T and Verma IM: CBP/p300 interact with and function as transcriptional coactivators of BRCA1. Proc Natl Acad Sci USA 97: 1020-1025, 2000. (Pubitemid 30080805)
11. Zhang H, Somasundaram K, Peng Y, Tian H, Zhang H, Bi D, Weber B and El-Deiry WS: BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 16: 1713-1721, 1998. (Pubitemid 28175052)
12. Ouchi T, Monteiro AN, August A, Aaronson SA and Hanafusa H: BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci USA 95: 2302-2306, 1998. (Pubitemid 28145936)
13. Chai YL, Cui J, Shao N, Shyam E, Reddy P and Rao VN: The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter. Oncogene 18: 263-268, 1999. (Pubitemid 29060601)
14. Lane DP and Crawford LV: T antigen is bound to a host protein in SV40-transformed cells. Nature 278: 261-263, 1979. (Pubitemid 9129076)
15. Linzer DI and Levine AJ: Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17: 43-52, 1979. (Pubitemid 9188209)
16. Stürzbecher HW, Brain R, Addison C, Rudge K, Remm M, Grimaldi M, Keenan E and Jenkins JR: A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene 7: 1513-1523, 1992.
17. Ko LJ and Prives C: p53: puzzle and paradigm. Genes Dev 10: 1054-1072, 1996. (Pubitemid 26152848)
18. Somasundaram K, Zhang H, Zeng YX, Houvras Y, Peng Y, Zhang H, Wu GS, Licht JD, Weber BL and El-Deiry WS: Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature 389: 187-190, 1997. (Pubitemid 27400601)
19. Miyashita T and Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299, 1995.
20. Greenblatt MS, Chappuis PO, Bond JP, Hamel N and Foulkes WD: TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res 61: 4092-4097, 2001. (Pubitemid 32720976)
21. Katsama A, Sourvinos G, Zachos G and Spandidos DA: Allelic loss at the BRCA1, BRCA2 and TP53 loci in human sporadic breast carcinoma. Cancer Lett 150: 165-170, 2000. (Pubitemid 30125850)
22. Easton DF, Bishop DT, Ford D and Crockford GP: Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 52: 678-701, 1993. (Pubitemid 23310135)
23. Futreal PA, Liu Q, Shattuck-Eidens D, et al: BRCA1 mutations in primary breast and ovarian carcinomas. Science 266: 120-122, 1994. (Pubitemid 24345332)
24. Gayther SA, Warren W, Mazoyer S, et al: Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 11: 428-433, 1995.
25. Brzovic PS, Rajagopal P, Hoyt DW, King MC and Klevit RE: Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nat Struct Biol 8: 833-837, 2001. (Pubitemid 32923599)
26. Shen D and Vadgama JV: BRCA1 and BRCA2 gene mutation analysis: visit to the Breast Cancer Information Core (BIC). Oncol Res 11: 63-69, 1999.
27. Quaresima B, Alifano P, Tassone P, Avvedimento VE, Costanzo FS and Venuta S: Human mismatch-repair protein MutL homologue 1 (MLH1) interacts with Escherichia coli MutL and MutS in vivo and in vitro: a simple genetic system to assay MLH1 function. Biochem J 371: 183-189, 2003. (Pubitemid 36458092)
28. Abkevich V, Zharkikh A, Deffenbaugh M, Frank D, Chen Y, Shattuck D, Skolnick MH, Gutin A and Tavtigian SV: Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet 41: 492-507, 2004. (Pubitemid 38932109)
29. Rosen EM, Fan S, Pestell RG and Goldberg ID: BRCA1 gene in breast cancer. J Cell Physiol 196: 19-41, 2003. (Pubitemid 36676440)
30. Williams RS, Chasman DI, Hau DD, Hui B, Lau AY and Glover JN: Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations. J Biol Chem 278: 53007-53016, 2003. (Pubitemid 38035903)
31. Gaiser OJ, Ball LJ, Schmieder P, Leitner D, Strauss H, Wahl M, Kuhne R, Oschkinat H and Heinemann U: Solution structure, backbone dynamics, and association behavior of the C-terminal BRCT domain from the breast cancer-associated protein BRCA1. Biochemistry 43: 15983-15995, 2004. (Pubitemid 40041012)
32. Mirkovic N, Marti-Renom MA, Weber BL, Sali A and Monteiro AN: Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition. Cancer Res 64: 3790-3797, 2004. (Pubitemid 38701757)
33. Joo WS, Jeffrey PD, Cantor SB, Finnin MS, Livingston DM and Pavletich NP: Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure. Genes Dev 16: 583-593, 2002. (Pubitemid 34212491)
34. Phelan CM, Apic V, Tice B, Favis R, Kwan E, Barany F, Manoukian S, Radice P, van der Luijt RB, van Nesselrooij BPM, Chenevix-Trench G, kConFab, Caldes T, de la Hoya M, Lindquist S, Tavtigian SV, Goldgar D, Borg Å, Narod SA and Monteiro ANA: Classification of BRCA1 missense variants of unknown clinical significance. J Med Gen 42: 138-146, 2005.
35. Shin SI, Freedman VH, Risser R and Pollack R: Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci USA 72: 4435-4439, 1975.
36. Thompson ME, Jensen RA, Obermiller PS, Page DL and Holt JT: Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 9: 444-450, 1995.